Gepride M 2 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 1000mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The sustained-release formulation ensures a gradual release of metformin, minimizing gastrointestinal side effects commonly associated with immediate-release forms and enhancing patient compliance. Gepride M 2 Forte is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with metformin, especially in patients with renal impairment. Contraindications include severe renal or hepatic dysfunction, metabolic acidosis, and hypersensitivity to components. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Dose adjustments should be individualized based on therapeutic response and tolerability under medical supervision.